GSBS Dissertations and Theses

ORCID ID

0000-0001-9990-4998

Approval Date

4-10-2018

Document Type

Doctoral Dissertation

Academic Program

MD/PhD

Department

Biochemistry and Molecular Pharmacology

First Thesis Advisor

Celia A. Schiffer, Ph.D.

Keywords

Hepacivirus, NS3/4A Protease, Viral Nonstructural Proteins, Protease Inhibitors, Hepatitis C virus, Drug Resistance

Abstract

The Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs) have become a mainstay of newer all-oral combination therapies. Despite improvements in potency of this inhibitor class, drug resistance remains a problem with the rapid emergence of resistance-associated substitutions (RASs). In this thesis I elucidate the molecular mechanisms of drug resistance for PIs against a resistant variant and apply insights toward the design of inhibitors with improved resistance profiles using structural, biochemical and computational techniques. Newer generation PIs retain high potency against most single substitutions in the protease active site by stacking on the catalytic triad. I investigated the molecular mechanisms of resistance against the Y56H/D168A variant. My analysis revealed that the Y56H substitution disrupts these inhibitors’ favorable stacking interactions with the catalytic residue His57.

To further address the impact of drug resistance, I designed new inhibitors that minimize contact with known drug resistance residues that are unessential in substrate recognition. The initially designed inhibitors exhibited flatter resistance profiles than the newer generation PIs but lost potency against the D168A variant. Finally, I designed inhibitors to extend into the substrate envelope (SE) and successfully regained potency against RAS variants maintaining a flat profile. These inhibitors both pack well in the enzyme and fit within the SE. Together these studies elucidate the molecular mechanisms of PI resistance and highlight the importance of substrate recognition in inhibitor design. The insights from this thesis provide strategies toward the development of diverse NS3/4A PIs that may one day lead to the eradication of HCV.

DOI

10.13028/M23X3H

Rights and Permissions

Copyright is held by the author, with all rights reserved.

Available for download on Saturday, May 04, 2019

Share

COinS